Replimune Group (NASDAQ:REPL) was upgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $26.00 price objective on the stock, down from their previous price objective of $27.00. JPMorgan Chase & Co.‘s price target points to a potential upside of 98.17% from the company’s previous close.

Several other analysts also recently commented on the stock. Wedbush cut their price objective on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 24th. HC Wainwright set a $73.00 price objective on shares of Uniqure and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Six analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $24.67.

Shares of REPL stock opened at $13.12 on Friday. Replimune Group has a one year low of $8.88 and a one year high of $23.55. The company’s 50-day moving average price is $13.53. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in shares of Replimune Group by 2.5% during the 4th quarter. Northern Trust Corp now owns 81,234 shares of the company’s stock valued at $813,000 after acquiring an additional 2,014 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new stake in shares of Replimune Group during the 1st quarter valued at about $38,000. Bank of New York Mellon Corp boosted its holdings in shares of Replimune Group by 21.2% during the 4th quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock valued at $240,000 after acquiring an additional 4,209 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Replimune Group during the 4th quarter valued at about $65,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Replimune Group by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 52,687 shares of the company’s stock valued at $526,000 after acquiring an additional 6,878 shares during the last quarter. 59.58% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: Purposes and Functions of the Federal Reserve

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.